The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer
H. Tsuda, Y. Hashiguchi, S. Nakata, M. Deguchi, S. Negoro, O. Ishiko, K. Yamamoto
International Journal of Gynecologic Cancer Aug 2002, 12 (5) 435-437; DOI: 10.1136/ijgc-00009577-200209000-00004